The study describes an in vitro assay for eukaryotic translation termination using antizyme frameshifting, revealing synergistic effects of eRF1 and eRF3 and dominant negative effects of eRF3 GTPase mutations.
Answers are grounded in this paper and cite their sources.
Preclinical findings only; leaves open the in vivo relevance of eRF1/eRF3 synergy for frameshifting regulation.
Translation termination in eukaryotes is mediated by the release factors eRF1 and eRF3, but mechanisms of the interplay between these factors are not fully understood, due partly to the difficulty of measuring termination on eukaryotic mRNAs. Here, we describe an in vitro system for the assay of termination using competition with programmed frameshifting at the recoding signal of mammalian antizyme. The efficiency of antizyme frameshifting in rabbit reticulocyte lysates was reduced by addition of recombinant rabbit eRF1 and eRF3 in a synergistic manner. Addition of suppressor tRNA to this assay system revealed competition with a third event, stop codon readthrough. Using these assays, we demonstrated that an eRF3 mutation at the GTPase domain repressed termination in a dominant negative fashion probably by binding to eRF1. The effect of the release factors and the suppressor tRNA showed that the stop codon at the antizyme frameshift site is relatively inefficient compared to either the natural termination signals at the end of protein coding sequences or the readthrough signal from a plant virus. The system affords a convenient assay for release factor activity and has provided some novel views of the mechanism of antizyme frameshifting.
No takes yet. Share an insight, caveat, or question.
Zemfira N. Karamysheva (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: